## **REMARKS**

New claims 40-54 are rpesented based on Claims 9-23 of commonly assigned U.S. patent 6,258,795 ('795 patent ). Claims 40 and 41 differ from Claims 10 and 11 in the '795 patent in that in Claims 40 and 41 it is stated that the composition is suitable for oral administration. Basis appears at page 34, lines 8 and 9. No new matter is entered.

Respectfully submitted,

**NIXON & VANDERHYE P.C.** 

By:

Reg. No. 29,009

LCM:Iks ្នាំ 1100 North Glebe Road, 8th Floor # Arlington, VA 22201-4714 Telephone: (703) 816-4000 ## Facsimile: (703) 816-4100

1

1 

H

[;] 44